The 2023 Endpoints 11; Regeneron’s gene editing ambitions; GSK’s research revamp; Ripple effect of Dana-Farber, Brigham breakup; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

While an Endpoints crew assembled in Boston for Endpoints 11, one of our biggest projects of the year, the rest of the team held down the fort and delivered excellent coverage from their corners of the world. We take a look at Regeneron’s bet gene editing delivery, GSK’s research revamp, the impact of the breakup between Dana-Farber and Brigham and Women’s Hospital, notable startup launches, and more.

The 2023 Endpoints 11

Endpoints once again spotlighted 11 of the biotech startups making the biggest bets with the most exciting science in the Endpoints 11 special report and accompanying event in…
Click here to view original post